Recombinant NKG2A (Monalizumab Biosimilar) anticorps
Research Grade
Reactivité: Humain
ELISA, WB
Hôte: Humanized
Monoclonal
unconjugated
Recombinant Antibody
-
- Antigène Tous les produits NKG2A (Monalizumab Biosimilar)
- NKG2A (Monalizumab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
- Reactivité
- Humain
-
Hôte
-
Humanized
- Expression System
- Mammalian cells
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp NKG2A (Monalizumab Biosimilar) est non-conjugé
- Application
- ELISA, Western Blotting (WB)
- Fonction
- Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade
- Attributs du produit
- Antibody Type: IgG4-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Pureté
- > 85%
- Classe de qualité
- Research Grade
- Isotype
- IgG4
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS buffer PH7.5
- Stock
- -80 °C
- Stockage commentaire
- store at -80°C
-
- Antigène
- NKG2A (Monalizumab Biosimilar)
- Abstract
- NKG2A (Monalizumab Biosimilar) Produits
- Sujet
- Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
- Numéro CAS
- 1228763-95-8
-
Vous êtes ici:
